View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

ALX Oncology to Present at Upcoming Investor Conferences

ALX Oncology to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37th Annual Global Healthcare Conference in New York. The details of the meetings are as follows: Jefferies Global Healthc...

 PRESS RELEASE

Freshpet, Inc. to Participate in the Morgan Stanley Global Consumer & ...

Freshpet, Inc. to Participate in the Morgan Stanley Global Consumer & Retail Conference BEDMINSTER, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that members of the executive management team will participate in the Morgan Stanley Global Consumer & Retail Conference in New York, NY. The fireside chat will be on Tuesday, December 2, 2025 at 4:30 p.m. ET. A live webcast and replay will be available on the "Investors" section of the Company's website at About FreshpetFreshpet's mission is to elevate the way we feed our ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides...

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levels Phase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026 Cash runway expe...

 PRESS RELEASE

Freshpet, Inc. to Participate in the J.P. Morgan U.S. Opportunities Fo...

Freshpet, Inc. to Participate in the J.P. Morgan U.S. Opportunities Forum BEDMINSTER, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that members of the executive management team will participate in the J.P. Morgan U.S. Opportunities Forum in Miami, FL. The fireside chat will be on Wednesday, November 12, 2025 at 11:45 a.m. ET. A live webcast and replay will be available on the "Investors" section of the Company's website at About FreshpetFreshpet's mission is to elevate the way we feed our pets with fresh food that n...

 PRESS RELEASE

Freshpet CEO to Adopt Rule 10b5-1 Trading Plan

Freshpet CEO to Adopt Rule 10b5-1 Trading Plan BEDMINSTER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that Billy Cyr, Chief Executive Officer, and various family members and independently managed trusts established for his family, intend to adopt prearranged trading plans in order to exercise options granted in 2016 which expire on September 6, 2026 and to sell shares necessary to cover the exercise price, taxes and various estate planning needs. These plans will not include any other Freshpet equity beyond the optio...

 PRESS RELEASE

Freshpet, Inc. Reports Third Quarter 2025 Financial Results

Freshpet, Inc. Reports Third Quarter 2025 Financial Results Net Sales Growth of 14% Outperforms CategoryCompany Achieves Positive Free Cash Flow in Third Quarter and Now Expects to be Free Cash Flow Positive in 2025Updates 2025 Guidance BEDMINSTER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its third quarter and nine months ended September 30, 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $288.8 million, an increase of 14.0%.Gross margin of 39.5%, com...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeli...

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market ope...

 PRESS RELEASE

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress ...

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference -Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC class and continued evaluation in first-in-human trial -Initial safety data from ongoing ALX2004 Phase 1 trial anticipated in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Oct. 23,...

 PRESS RELEASE

Freshpet, Inc. to Report Third Quarter 2025 Results on Monday, Novembe...

Freshpet, Inc. to Report Third Quarter 2025 Results on Monday, November 3, 2025 BEDMINSTER, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (Nasdaq: FRPT) (“Freshpet” or the “Company”) today announced it will report results for the third quarter ended September 30, 2025 on Monday, November 3, 2025 before market open. The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 8:00 a.m. ET on Monday, November 3, 2025. To participate on the live call,...

 PRESS RELEASE

Freshpet Announces CFO Transition Process

Freshpet Announces CFO Transition Process Ivan Garcia Appointed Interim CFO Company Reaffirms 2025 Outlook BEDMINSTER, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today announced that Ivan Garcia, Vice President of Finance, has been named Interim Chief Financial Officer, effective October 17, 2025. Mr. Garcia will succeed Todd Cunfer, who has made the decision to accept an opportunity outside the Company. Mr. Cunfer will remain with the Company until October 17, 2025 to support Mr. Garcia in the transition. Freshpet has commenced a...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, High...

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel th...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 26, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

NextDecade Corp: 2 directors

Two Directors at NextDecade Corp bought 115,000 shares at between 6.456USD and 6.864USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch